Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Conditional, inducible gene silencing in dopamine neurons reveals a sex-specific role for Rit2 GTPase in acute cocaine response and striatal function.

Sweeney CG, Kearney PJ, Fagan RR, Smith LA, Bolden NC, Zhao-Shea R, Rivera IV, Kolpakova J, Xie J, Gao G, Tapper AR, Martin GE, Melikian HE.

Neuropsychopharmacology. 2020 Jan;45(2):384-393. doi: 10.1038/s41386-019-0457-x. Epub 2019 Jul 5.

PMID:
31277075
2.

The Dopamine Transporter Recycles via a Retromer-Dependent Postendocytic Mechanism: Tracking Studies Using a Novel Fluorophore-Coupling Approach.

Wu S, Fagan RR, Uttamapinant C, Lifshitz LM, Fogarty KE, Ting AY, Melikian HE.

J Neurosci. 2017 Sep 27;37(39):9438-9452. doi: 10.1523/JNEUROSCI.3885-16.2017. Epub 2017 Aug 28.

3.

Dopamine Transporter Amino and Carboxyl Termini Synergistically Contribute to Substrate and Inhibitor Affinities.

Sweeney CG, Tremblay BP, Stockner T, Sitte HH, Melikian HE.

J Biol Chem. 2017 Jan 27;292(4):1302-1309. doi: 10.1074/jbc.M116.762872. Epub 2016 Dec 16.

4.

Ack1 is a dopamine transporter endocytic brake that rescues a trafficking-dysregulated ADHD coding variant.

Wu S, Bellve KD, Fogarty KE, Melikian HE.

Proc Natl Acad Sci U S A. 2015 Dec 15;112(50):15480-5. doi: 10.1073/pnas.1512957112. Epub 2015 Nov 30.

5.
6.

Dopamine transporter endocytic trafficking in striatal dopaminergic neurons: differential dependence on dynamin and the actin cytoskeleton.

Gabriel LR, Wu S, Kearney P, Bellvé KD, Standley C, Fogarty KE, Melikian HE.

J Neurosci. 2013 Nov 6;33(45):17836-46. doi: 10.1523/JNEUROSCI.3284-13.2013.

7.

The acid-sensitive, anesthetic-activated potassium leak channel, KCNK3, is regulated by 14-3-3β-dependent, protein kinase C (PKC)-mediated endocytic trafficking.

Gabriel L, Lvov A, Orthodoxou D, Rittenhouse AR, Kobertz WR, Melikian HE.

J Biol Chem. 2012 Sep 21;287(39):32354-66. Epub 2012 Jul 30.

8.

The plasma membrane-associated GTPase Rin interacts with the dopamine transporter and is required for protein kinase C-regulated dopamine transporter trafficking.

Navaroli DM, Stevens ZH, Uzelac Z, Gabriel L, King MJ, Lifshitz LM, Sitte HH, Melikian HE.

J Neurosci. 2011 Sep 28;31(39):13758-70. doi: 10.1523/JNEUROSCI.2649-11.2011.

9.

Insertion of tetracysteine motifs into dopamine transporter extracellular domains.

Navaroli DM, Melikian HE.

PLoS One. 2010 Feb 9;5(2):e9113. doi: 10.1371/journal.pone.0009113.

10.

Dopamine transporter endocytic determinants: carboxy terminal residues critical for basal and PKC-stimulated internalization.

Boudanova E, Navaroli DM, Stevens Z, Melikian HE.

Mol Cell Neurosci. 2008 Oct;39(2):211-7. doi: 10.1016/j.mcn.2008.06.011. Epub 2008 Jun 25.

11.

Amphetamine-induced decreases in dopamine transporter surface expression are protein kinase C-independent.

Boudanova E, Navaroli DM, Melikian HE.

Neuropharmacology. 2008 Mar;54(3):605-12. doi: 10.1016/j.neuropharm.2007.11.007. Epub 2007 Nov 22.

12.
13.

Neurotransmitter transporter trafficking: endocytosis, recycling, and regulation.

Melikian HE.

Pharmacol Ther. 2004 Oct;104(1):17-27. Review.

PMID:
15500906
14.
15.

Regulation of neuronal function by protein trafficking: a role for the endosomal pathway.

Buckley KM, Melikian HE, Provoda CJ, Waring MT.

J Physiol. 2000 May 15;525 Pt 1:11-9. Review.

16.

Fragile X mouse: strain effects of knockout phenotype and evidence suggesting deficient amygdala function.

Paradee W, Melikian HE, Rasmussen DL, Kenneson A, Conn PJ, Warren ST.

Neuroscience. 1999;94(1):185-92.

PMID:
10613508
17.

Membrane trafficking regulates the activity of the human dopamine transporter.

Melikian HE, Buckley KM.

J Neurosci. 1999 Sep 15;19(18):7699-710.

18.

Biosynthesis, N-glycosylation, and surface trafficking of biogenic amine transporter proteins.

Ramamoorthy S, Melikian HE, Qian Y, Blakely RD.

Methods Enzymol. 1998;296:347-70. No abstract available.

PMID:
9779460
19.
20.
21.

Human norepinephrine transporter. Biosynthetic studies using a site-directed polyclonal antibody.

Melikian HE, McDonald JK, Gu H, Rudnick G, Moore KR, Blakely RD.

J Biol Chem. 1994 Apr 22;269(16):12290-7.

23.

Treatment of ligneous conjunctivitis.

Melikian HE.

Ann Ophthalmol. 1985 Dec;17(12):763-5.

PMID:
2936292
24.

Ocular abnormalities in patients with gout.

Ferry AP, Safir A, Melikian HE.

Ann Ophthalmol. 1985 Oct;17(10):632-5.

PMID:
4073719
25.

Ocular pigmentation and pressure and outflow responses to pilocarpine and epinephrine.

Melikian HE, Lieberman TW, Leopold IH.

Am J Ophthalmol. 1971 Jul 30;72(1):70-3. No abstract available.

PMID:
5571213
26.

Use of subconjunctival hyaluronidase.

Melikian HE, Nowakowski J, Boyle GL, Leopold IH.

Am J Ophthalmol. 1971 Jun;71(6):1313-6. No abstract available.

PMID:
5091130

Supplemental Content

Loading ...
Support Center